Metrion Biosciences launches validated high-throughput Nav1.9 screening assay for chronic pain research
Cambridge-based contract research organisation Metrion Biosciences has unveiled a breakthrough high-throughput screening assay targeting the Nav1.9 voltage-gated sodium channel, addressing a critical bottleneck in non-opioid pain therapeutic development. The validated assay platform promises to accelerate drug discovery programmes by overcoming traditional limitations that have hindered Nav1.9 research for years.


